TY - JOUR
T1 - Glycosphingolipid-associated β-1,4 galactosyltransferase is elevated in patients with systemic lupus erythematosus
AU - Sadras, Vignesh
AU - Petri, Michelle A.
AU - Jones, Steven Richard
AU - Peterlin, Barbara Lee
AU - Chatterjee, Subroto
AU - Chatterjee, Subroto
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2020/7/13
Y1 - 2020/7/13
N2 - Objective β-1,4 galactosyltransferase-V (β-1,4 GalT-V) is an enzyme that synthesises a glycosphingolipid known as lactosylceramide, which has been implicated in general inflammation and atherosclerosis. We asked if β-1,4 GalT-V was present at elevated levels in patients with SLE, a disease which is associated with increased risk of atherosclerosis. Methods In this case-control observational study, serum samples were obtained from patients with SLE who are part of the Johns Hopkins Lupus Cohort. Control serum samples were obtained from healthy adult community members recruited from the Baltimore area. All serum samples (n=50 in the SLE group and n=50 in the healthy control group) were analysed with enzyme-linked immunoassays. These assays used antibodies raised against antigens that enabled us to measure the absorbance of oxidised phosphocholines per apolipoprotein B-100 (ox-PC/apoB) and the concentration of lipoprotein(a) (Lp(a)) and β-1,4 GalT-V. Results Absorbance of ox-PC/apoB and concentrations of Lp(a) and β-1,4 GalT-V were significantly higher in the SLE serum samples as compared with the control serum (p<0.0001). Conclusions We conclude that patients with SLE have elevated levels of β-1,4 GalT-V and ox-PC, which have previously been recognised as risk factors for atherosclerosis.
AB - Objective β-1,4 galactosyltransferase-V (β-1,4 GalT-V) is an enzyme that synthesises a glycosphingolipid known as lactosylceramide, which has been implicated in general inflammation and atherosclerosis. We asked if β-1,4 GalT-V was present at elevated levels in patients with SLE, a disease which is associated with increased risk of atherosclerosis. Methods In this case-control observational study, serum samples were obtained from patients with SLE who are part of the Johns Hopkins Lupus Cohort. Control serum samples were obtained from healthy adult community members recruited from the Baltimore area. All serum samples (n=50 in the SLE group and n=50 in the healthy control group) were analysed with enzyme-linked immunoassays. These assays used antibodies raised against antigens that enabled us to measure the absorbance of oxidised phosphocholines per apolipoprotein B-100 (ox-PC/apoB) and the concentration of lipoprotein(a) (Lp(a)) and β-1,4 GalT-V. Results Absorbance of ox-PC/apoB and concentrations of Lp(a) and β-1,4 GalT-V were significantly higher in the SLE serum samples as compared with the control serum (p<0.0001). Conclusions We conclude that patients with SLE have elevated levels of β-1,4 GalT-V and ox-PC, which have previously been recognised as risk factors for atherosclerosis.
KW - atherosclerosis
KW - inflammation
KW - lipids
KW - systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=85088521919&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088521919&partnerID=8YFLogxK
U2 - 10.1136/lupus-2019-000368
DO - 10.1136/lupus-2019-000368
M3 - Article
C2 - 32665303
AN - SCOPUS:85088521919
SN - 2053-8790
VL - 7
JO - Lupus Science and Medicine
JF - Lupus Science and Medicine
IS - 1
M1 - e000368
ER -